The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smyth, M. J.
Right arrow Articles by Scalzo, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smyth, M. J.
Right arrow Articles by Scalzo, A. A.
The Journal of Immunology, 1999, 162: 6658-6662.
Copyright © 1999 by The American Association of Immunologists

Perforin Is a Major Contributor to NK Cell Control of Tumor Metastasis1

Mark J. Smyth2,*, Kevin Y. T. Thia*, Erika Cretney*, Janice M. Kelly*, Marie B. Snook*, Catherine A. Forbes{dagger} and Anthony A. Scalzo{dagger}

* Cellular Immunity Laboratory, Austin Research Institute, Heidelberg, Victoria, Australia; and {dagger} Department of Microbiology, University of Western Australia, Nedlands, Western Australia, Australia

We provide the first demonstration, using experimental and spontaneous models of metastasis in C57BL/6 (B6) (RM-1 prostate carcinoma) and BALB/c (DA3 mammary carcinoma) mice, that tumor metastasis is primarily controlled by perforin-dependent cytotoxicity mediated by NK1.1+ cells. MHC class Ilow RM-1 and DA3 tumor cells were sensitive in vitro to Fas-mediated lysis or spleen NK cells in a perforin-dependent fashion. Perforin-deficient NK cells did not lyse these tumors, and perforin-deficient mice were 10–100-fold less proficient than wild-type mice in rejecting the metastasis of tumor cells to the lung. Fas ligand mutant gld mice displayed uncompromised protection against tumor metastasis. Depletion of NK subsets resulted in greater numbers of metastases than observed in perforin-deficient mice, suggesting that perforin-independent effector functions of NK cells may also contribute to protection from tumor metastasis.




This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
B. N. Alves, J. Leong, D. L. Tamang, V. Elliott, J. Edelnant, D. Redelman, C. A. Singer, A. R. Kuhn, R. Miller, M. E. Lowe, et al.
Pancreatic lipase-related protein 2 (PLRP2) induction by IL-4 in cytotoxic T lymphocytes (CTLs) and reevaluation of the negative effects of its gene ablation on cytotoxicity
J. Leukoc. Biol., September 1, 2009; 86(3): 701 - 712.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
Y. KAWAGUCHI, K. KONO, Y. MIZUKAMI, K. MIMURA, and H. FUJII
Mechanisms of Escape from Trastuzumab-mediated ADCC in Esophageal Squamous Cell Carcinoma: Relation to Susceptibility to Perforin-granzyme
Anticancer Res, June 1, 2009; 29(6): 2137 - 2146.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
D Engelmann, D Koczan, P Ricken, U Rimpler, J Pahnke, Z Li, and B M Putzer
Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance
Endocr. Relat. Cancer, March 1, 2009; 16(1): 211 - 224.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. H. Schreiber, V. V. Deyev, J. D. Rosenblatt, and E. R. Podack
Tumor-Induced Suppression of CTL Expansion and Subjugation by gp96-Ig Vaccination
Cancer Res., March 1, 2009; 69(5): 2026 - 2033.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. Bolitho, S. E. A. Street, J. A. Westwood, W. Edelmann, D. MacGregor, P. Waring, W. K. Murray, D. I. Godfrey, J. A. Trapani, R. W. Johnstone, et al.
Perforin-mediated suppression of B-cell lymphoma
PNAS, February 24, 2009; 106(8): 2723 - 2728.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. B. F. Werneck, G. Lugo-Villarino, E. S. Hwang, H. Cantor, and L. H. Glimcher
T-Bet Plays a Key Role in NK-Mediated Control of Melanoma Metastatic Disease
J. Immunol., June 15, 2008; 180(12): 8004 - 8010.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Binyamin, R. K. Alpaugh, T. L. Hughes, C. T. Lutz, K. S. Campbell, and L. M. Weiner
Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy
J. Immunol., May 1, 2008; 180(9): 6392 - 6401.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. J. Smyth, M. W.L. Teng, J. Sharkey, J. A. Westwood, N. M. Haynes, H. Yagita, K. Takeda, P. V. Sivakumar, and M. H. Kershaw
Interleukin 21 Enhances Antibody-Mediated Tumor Rejection
Cancer Res., April 15, 2008; 68(8): 3019 - 3025.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. M. Greeneltch, M. Schneider, S. M. Steinberg, D. J. Liewehr, T. J. Stewart, K. Liu, and S. I. Abrams
Host Immunosurveillance Controls Tumor Growth via IFN Regulatory Factor-8 Dependent Mechanisms
Cancer Res., November 1, 2007; 67(21): 10406 - 10416.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. Voskoboinik, V. R. Sutton, A. Ciccone, C. M. House, J. Chia, P. K. Darcy, H. Yagita, and J. A. Trapani
Perforin activity and immune homeostasis: the common A91V polymorphism in perforin results in both presynaptic and postsynaptic defects in function
Blood, August 15, 2007; 110(4): 1184 - 1190.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. B. Swann, Y. Hayakawa, N. Zerafa, K. C. F. Sheehan, B. Scott, R. D. Schreiber, P. Hertzog, and M. J. Smyth
Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function
J. Immunol., June 15, 2007; 178(12): 7540 - 7549.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. E.A. Street, N. Zerafa, M. Iezzi, J. A. Westwood, J. Stagg, P. Musiani, and M. J. Smyth
Host Perforin Reduces Tumor Number but Does Not Increase Survival in Oncogene-Driven Mammary Adenocarcinoma
Cancer Res., June 1, 2007; 67(11): 5454 - 5460.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Zamai, C. Ponti, P. Mirandola, G. Gobbi, S. Papa, L. Galeotti, L. Cocco, and M. Vitale
NK Cells and Cancer
J. Immunol., April 1, 2007; 178(7): 4011 - 4016.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. H. Johansson, M. A. Taylor, M. Jagodic, K. Tus, J. D. Schatzle, E. K. Wakeland, and M. Bennett
Mapping of Quantitative Trait Loci Determining NK Cell-Mediated Resistance to MHC Class I-Deficient Bone Marrow Grafts in Perforin-Deficient Mice
J. Immunol., December 1, 2006; 177(11): 7923 - 7929.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Abdool, E. Cretney, A. D. Brooks, J. M. Kelly, J. Swann, A. Shanker, E. W. Bere Jr., W. M. Yokoyama, J. R. Ortaldo, M. J. Smyth, et al.
NK Cells Use NKG2D to Recognize a Mouse Renal Cancer (Renca), yet Require Intercellular Adhesion Molecule-1 Expression on the Tumor Cells for Optimal Perforin-Dependent Effector Function
J. Immunol., August 15, 2006; 177(4): 2575 - 2583.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Lundqvist, S. I. Abrams, D. S. Schrump, G. Alvarez, D. Suffredini, M. Berg, and R. Childs
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Cancer Res., July 15, 2006; 66(14): 7317 - 7325.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Smyth, Y. Hayakawa, E. Cretney, N. Zerafa, P. Sivakumar, H. Yagita, and K. Takeda
IL-21 Enhances Tumor-Specific CTL Induction by Anti-DR5 Antibody Therapy
J. Immunol., May 15, 2006; 176(10): 6347 - 6355.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Liu, S. Yu, K. Zinn, J. Wang, L. Zhang, Y. Jia, J. C. Kappes, S. Barnes, R. P. Kimberly, W. E. Grizzle, et al.
Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function
J. Immunol., February 1, 2006; 176(3): 1375 - 1385.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Smyth, M. W. L. Teng, J. Swann, K. Kyparissoudis, D. I. Godfrey, and Y. Hayakawa
CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer
J. Immunol., February 1, 2006; 176(3): 1582 - 1587.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. J. Smyth, J. Swann, E. Cretney, N. Zerafa, W. M. Yokoyama, and Y. Hayakawa
NKG2D function protects the host from tumor initiation
J. Exp. Med., September 6, 2005; 202(5): 583 - 588.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. I. Pao, N. Sumaria, J. M. Kelly, S. v. Dommelen, E. Cretney, M. E. Wallace, D. A. Anthony, A. P. Uldrich, D. I. Godfrey, J. M. Papadimitriou, et al.
Functional Analysis of Granzyme M and Its Role in Immunity to Infection
J. Immunol., September 1, 2005; 175(5): 3235 - 3243.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Takaki, Y. Hayakawa, A. Nelson, P. V. Sivakumar, S. Hughes, M. J. Smyth, and L. L. Lanier
IL-21 Enhances Tumor Rejection through a NKG2D-Dependent Mechanism
J. Immunol., August 15, 2005; 175(4): 2167 - 2173.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. J. Smyth, M. E. Wallace, S. L. Nutt, H. Yagita, D. I. Godfrey, and Y. Hayakawa
Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer
J. Exp. Med., June 20, 2005; 201(12): 1973 - 1985.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Esplugues, J. Vega-Ramos, D. Cartoixa, B. N. Vazquez, I. Salaet, P. Engel, and P. Lauzurica
Induction of tumor NK-cell immunity by anti-CD69 antibody therapy
Blood, June 1, 2005; 105(11): 4399 - 4406.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Clementi, F. Locatelli, L. Dupre, A. Garaventa, L. Emmi, M. Bregni, G. Cefalo, A. Moretta, C. Danesino, M. Comis, et al.
A proportion of patients with lymphoma may harbor mutations of the perforin gene
Blood, June 1, 2005; 105(11): 4424 - 4428.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Liu, S. A. Caldwell, and S. I. Abrams
Immune Selection and Emergence of Aggressive Tumor Variants as Negative Consequences of Fas-Mediated Cytotoxicity and Altered IFN-{gamma}-Regulated Gene Expression
Cancer Res., May 15, 2005; 65(10): 4376 - 4388.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. J. Smyth, J. Swann, J. M. Kelly, E. Cretney, W. M. Yokoyama, A. Diefenbach, T. J. Sayers, and Y. Hayakawa
NKG2D Recognition and Perforin Effector Function Mediate Effective Cytokine Immunotherapy of Cancer
J. Exp. Med., November 15, 2004; 200(10): 1325 - 1335.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
I. Voskoboinik, M.-C. Thia, A. De Bono, K. Browne, E. Cretney, J. T. Jackson, P. K. Darcy, S. M. Jane, M. J. Smyth, and J. A. Trapani
The Functional Basis for Hemophagocytic Lymphohistiocytosis in a Patient with Co-inherited Missense Mutations in the Perforin (PFN1) Gene
J. Exp. Med., September 20, 2004; 200(6): 811 - 816.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
S. E.A. Street, Y. Hayakawa, Y. Zhan, A. M. Lew, D. MacGregor, A. M. Jamieson, A. Diefenbach, H. Yagita, D. I. Godfrey, and M. J. Smyth
Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and {gamma}{delta} T Cells
J. Exp. Med., March 15, 2004; 199(6): 879 - 884.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Brady, Y. Hayakawa, M. J. Smyth, and S. L. Nutt
IL-21 Induces the Functional Maturation of Murine NK Cells
J. Immunol., February 15, 2004; 172(4): 2048 - 2058.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Hayakawa, V. Screpanti, H. Yagita, A. Grandien, H.-G. Ljunggren, M. J. Smyth, and B. J. Chambers
NK Cell TRAIL Eliminates Immature Dendritic Cells In Vivo and Limits Dendritic Cell Vaccination Efficacy
J. Immunol., January 1, 2004; 172(1): 123 - 129.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Smyth, S. E. A. Street, and J. A. Trapani
Cutting Edge: Granzymes A and B Are Not Essential for Perforin-Mediated Tumor Rejection
J. Immunol., July 15, 2003; 171(2): 515 - 518.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. L. H. van Dommelen, H. A. Tabarias, M. J. Smyth, and M. A. Degli-Esposti
Activation of Natural Killer (NK) T Cells during Murine Cytomegalovirus Infection Enhances the Antiviral Response Mediated by NK Cells
J. Virol., February 1, 2003; 77(3): 1877 - 1884.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Seki, Y. Hayakawa, A. D. Brooks, J. Wine, R. H. Wiltrout, H. Yagita, J. E. Tanner, M. J. Smyth, and T. J. Sayers
Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated Apoptosis Is an Important Endogenous Mechanism for Resistance to Liver Metastases in Murine Renal Cancer
Cancer Res., January 1, 2003; 63(1): 207 - 213.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Hayakawa, J. M. Kelly, J. A. Westwood, P. K. Darcy, A. Diefenbach, D. Raulet, and M. J. Smyth
Cutting Edge: Tumor Rejection Mediated by NKG2D Receptor-Ligand Interaction Is Dependent upon Perforin
J. Immunol., November 15, 2002; 169(10): 5377 - 5381.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Ogasawara, S. K. Yoshinaga, and L. L. Lanier
Inducible Costimulator Costimulates Cytotoxic Activity and IFN-{gamma} Production in Activated Murine NK Cells
J. Immunol., October 1, 2002; 169(7): 3676 - 3685.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. A. Pulaski, M. J. Smyth, and S. Ostrand-Rosenberg
Interferon-{gamma}-dependent Phagocytic Cells Are a Critical Component of Innate Immunity against Metastatic Mammary Carcinoma
Cancer Res., August 1, 2002; 62(15): 4406 - 4412.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
S. E.A. Street, J. A. Trapani, D. MacGregor, and M. J. Smyth
Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon {gamma}
J. Exp. Med., July 1, 2002; 196(1): 129 - 134.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. M. Kelly, K. Takeda, P. K. Darcy, H. Yagita, and M. J. Smyth
A Role for IFN-{gamma} in Primary and Secondary Immunity Generated by NK Cell-Sensitive Tumor-Expressing CD80 In Vivo
J. Immunol., May 1, 2002; 168(9): 4472 - 4479.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Seki, A. D. Brooks, C. R. D. Carter, T. C. Back, E. M. Parsoneault, M. J. Smyth, R. H. Wiltrout, and T. J. Sayers
Tumor-Specific CTL Kill Murine Renal Cancer Cells Using Both Perforin and Fas Ligand-Mediated Lysis In Vitro, But Cause Tumor Regression In Vivo in the Absence of Perforin
J. Immunol., April 1, 2002; 168(7): 3484 - 3492.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. J. Smyth, N. Y. Crowe, D. G. Pellicci, K. Kyparissoudis, J. M. Kelly, K. Takeda, H. Yagita, and D. I. Godfrey
Sequential production of interferon-gamma by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of alpha -galactosylceramide
Blood, February 15, 2002; 99(4): 1259 - 1266.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J. J. Peschon, and M. J. Smyth
Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice
J. Immunol., February 1, 2002; 168(3): 1356 - 1361.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Schmaltz, O. Alpdogan, K. J. Horndasch, S. J. Muriglan, B. J. Kappel, T. Teshima, J. L. M. Ferrara, S. J. Burakoff, and M. R. M. van den Brink
Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect
Blood, May 1, 2001; 97(9): 2886 - 2895.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
M. J. Smyth, N. Y. Crowe, and D. I. Godfrey
NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
Int. Immunol., April 1, 2001; 13(4): 459 - 463.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. J. Smyth, E. Cretney, K. Takeda, R. H. Wiltrout, L. M. Sedger, N. Kayagaki, H. Yagita, and K. Okumura
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon {gamma}-Dependent Natural Killer Cell Protection from Tumor Metastasis
J. Exp. Med., March 19, 2001; 193(6): 661 - 670.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. E. A. Street, E. Cretney, and M. J. Smyth
Perforin and interferon-{gamma} activities independently control tumor initiation, growth, and metastasis
Blood, January 1, 2001; 97(1): 192 - 197.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. J. Smyth, K. Y.T. Thia, S. E.A. Street, D. MacGregor, D. I. Godfrey, and J. A. Trapani
Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma
J. Exp. Med., September 5, 2000; 192(5): 755 - 760.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Smyth, M. Taniguchi, and S. E. A. Street
The Anti-Tumor Activity of IL-12: Mechanisms of Innate Immunity That Are Model and Dose Dependent
J. Immunol., September 1, 2000; 165(5): 2665 - 2670.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Lehmann, M. Zeis, N. Schmitz, and L. Uharek
Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells
Blood, July 15, 2000; 96(2): 594 - 600.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Prevost-Blondel, E. Roth, F. M. Rosenthal, and H. Pircher
Crucial Role of TNF-{alpha} in CD8 T Cell-Mediated Elimination of 3LL-A9 Lewis Lung Carcinoma Cells In Vivo
J. Immunol., April 1, 2000; 164(7): 3645 - 3651.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M. J. Smyth, K. Y. T. Thia, S. E.A. Street, E. Cretney, J. A. Trapani, M. Taniguchi, T. Kawano, S. B. Pelikan, N. Y. Crowe, and D. I. Godfrey
Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
J. Exp. Med., February 21, 2000; 191(4): 661 - 668.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Smyth, R. W. Johnstone, E. Cretney, N. M. Haynes, J. D. Sedgwick, H. Korner, L. D. Poulton, and A. G. Baxter
Multiple Deficiencies Underlie NK Cell Inactivity in Lymphotoxin-{alpha} Gene-Targeted Mice
J. Immunol., August 1, 1999; 163(3): 1350 - 1353.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.